INCYTE CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.86 USD | -0.14% |
|
+3.53% | -15.62% |
| May. 01 | TD Cowen Adjusts Price Target on Incyte to $80 From $88 | MT |
| May. 01 | RBC Capital Adjusts Price Target on Incyte to $60 From $65 | MT |
Financials (USD)
| Sales 2024 * | 4.09B | Sales 2025 * | 4.52B | Capitalization | 11.89B |
|---|---|---|---|---|---|
| Net income 2024 * | 765M | Net income 2025 * | 970M | EV / Sales 2024 * | 1.87 x |
| Net cash position 2024 * | 4.25B | Net cash position 2025 * | 5.5B | EV / Sales 2025 * | 1.41 x |
| P/E ratio 2024 * |
16.2
x | P/E ratio 2025 * |
13
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +0.05% | ||
| 1 week | +3.56% | ||
| Current month | +1.83% | ||
| 1 month | -5.07% | ||
| 3 months | -9.17% | ||
| 6 months | -1.80% | ||
| Current year | -15.59% |
1 week
50.35
53.98
1 month
50.3556.46
Current year
50.3567.37
1 year
50.2769.83
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Pablo Cagnoni
PSD | President | 60 | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 215 M€ | +12.12% | - | |
| 2.94% | 1 M€ | -4.80% | - | |
| 2.88% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 52.98 | +0.08% | 391 615 |
| 24-05-01 | 52.94 | +1.71% | 3,577,694 |
| 24-04-30 | 52.05 | -0.97% | 4,773,335 |
| 24-04-29 | 52.56 | +1.70% | 3,081,703 |
| 24-04-26 | 51.68 | +0.98% | 1,564,403 |
Delayed Quote Nasdaq, May 02, 2024 at 11:16 am EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
52.94
USD
Average target price
73.53
USD
Spread / Average Target
+38.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.59% | 11.89B | |
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -16.99% | 31.47B | |
| +54.18% | 25.24B | |
| -12.97% | 15.82B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +5.02% | 8.84B | |
| -2.11% | 7.93B |
- Stock Market
- Equities
- INCY Stock
